Vaccination greatly reduces disease, disability, death and inequity worldwide. Vaccines even permitted total eradication of Small Pox. However, most vaccines available today are still manufactured with the original process technologies in complex and capital-intensive facilities. The labor-intensive, low-yield and low throughput processes, and the lack of manufacturing flexibility diminish affordability for developing countries, forcing manufacturers to address the problem by supplying these markets with subsidized products and/or non-sustainable prices. Advancements in vaccines manufacturing would benefit both global health and the industry. This presentation will focus on a new holistic approach that integrates tested strategies for cost efficient manufacturing of vaccines, linking innovations in cell line development, bioreactor design, membrane chromatography and flexible facility design for a 500-fold increase in overall productivity. This end-to-end, next generation facility merging high productivity technologies to achieve simplified process architecture, increased robustness and augmented yield can be replicated anywhere to make production in developing countries in need of vaccines a reality. It will contribute to supplying annually 40M doses of vaccines at &lt;$0.15/dose from a $10M facility, and could therefore support eradication of poliomyelitis in the next 10 years.

Next-generation vaccine facility: Merging high productivity technologies for robust and cost-effective manufacturing

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.